Hansa Biopharma AB (publ) (STO: HNSA)
Sweden
· Delayed Price · Currency is SEK
55.20
+3.25 (6.26%)
Aug 30, 2024, 5:29 PM CET
Hansa Biopharma AB Revenue
Hansa Biopharma AB had revenue of 34.33M SEK in the quarter ending June 30, 2024, a decrease of -6.32%. This brings the company's revenue in the last twelve months to 163.56M, up 3.07% year-over-year. In the year 2023, Hansa Biopharma AB had annual revenue of 134.09M, down -13.22%.
Revenue (ttm)
163.56M
Revenue Growth
+3.07%
P/S Ratio
18.64
Revenue / Employee
1.12M
Employees
168
Market Cap
3.74B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 134.09M | -20.43M | -13.22% |
Dec 31, 2022 | 154.53M | 120.65M | 356.12% |
Dec 31, 2021 | 33.88M | 27.78M | 455.56% |
Dec 31, 2020 | 6.10M | 2.73M | 81.27% |
Dec 31, 2019 | 3.36M | 6.00K | 0.18% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca PLC | 520.76B |
Swedish Orphan Biovitrum AB (publ) | 23.71B |
Getinge AB (publ) | 33.33B |
Sectra AB (publ) | 3.04B |
Camurus AB (publ) | 1.59B |
Vitrolife AB (publ) | 3.54B |
Medicover AB (publ) | 21.70B |
Elekta AB (publ) | 18.12B |
Hansa Biopharma AB News
- 9 days ago - Hansa Biopharma Announces Departure of Chief Commercial Officer, Matthew Shaulis - PRNewsWire
- 6 weeks ago - Hansa Biopharma Reports Second Quarter 2024 Financial Results and Business Update - PRNewsWire
- 2 months ago - Hansa Biopharma to host Q2 2024 interim results conference call - PRNewsWire
- 2 months ago - Hansa Biopharma: increase in number of shares and votes - PRNewsWire
- 3 months ago - Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial - PRNewsWire
- 3 months ago - Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting - PRNewsWire
- 4 months ago - Hansa Biopharma interim report January-March 2024 - PRNewsWire
- 5 months ago - Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance - PRNewsWire